Answer
Evidence is still limited and recommendations require an individual specialist benefit–risk discussion. Treatment should not be started, stopped or interrupted because of pregnancy or breastfeeding without advice from the cystic fibrosis and maternity teams.
Sources for this answer
- Kaftrio 75 mg/50 mg/100 mg film-coated tabletsemc · SmPC Current selected SmPC · Version 16
- UK Teratology Information Service